Cybrdi, Inc.: Form 10-Q - Filed by newsfilecorp.com

[ X ] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

No 29 Chang'An South Road Xi'an Shaanxi P.R. China 71006 1
(Address of principal executive office) (Zip Code)

N/A
Former name, former address and former fiscal year, (if changed since last report)

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of "large accelerated filer", "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act. (Check one):

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

The number of shares of common stock, no par value per share, outstanding as of August 14, 2012 was 120,225,323.

CYBRDI, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
(UNAUDITED)

		Three Months Ended			Three Months Ended			Six Months Ended			Six Months Ended
		June 30, 2012			June 30, 2011			June 30, 2012			June 30, 2011
Revenue
Housing	$	-		$	-		$	142,200		$	-
Commercial rental		-			-			-			-
Tissue array products		112,407			123,419			212,317			237,230
Total revenue		112,407			123,419			354,517			237,230
Cost of Sales
Housing		-			-			123,306			-
Commercial rental		16,414			17,125			32,880			31,752
Tissue array products		65,120			102,176			144,434			189,324
Total cost of sales		81,534			119,301			300,620			221,076

Gross Profit		30,873			4,118			53,897			16,154

Operating Expenses:
Salaries and wages		50,316			41,093			102,560			81,576
Depreciation and amortization		36,561			36,721			75,008			72,993
Professional fees		19,026			10,783			37,735			57,108
Operating tax expenses		10,985			54			27,214			125
Selling and distribution expenses		1,374			3,786			2,753			10,211
Other general and administrative expenses		24,541			25,352			54,854			51,637
Bad debt expense		-			23,226			-			68,830
Total Operating Expenses		142,803			141,015			300,124			342,480

Loss from Operations		(111,930	)		(136,897	)		(246,227	)		(326,326	)

Other Income
Net interest expense		(46,132	)		(1,085	)		(92,122	)		(598	)
Other (expense) income, net		3,496			(14	)		(22,561	)		229
Total Other Expense, Net		(42,636	)		(1,099	)		(114,683	)		(369	)

Loss before Income Taxes		(154,566	)		(137,996	)		(360,910	)		(326,695	)
Income Tax Expense		(162	)		-			(162	)		-
Net loss		(154,728	)		(137,996	)		(361,072	)		(326,695	)
Net loss attributable to the noncontrolling interest		(29,860	)		(28,160	)		(68,325	)		(53,169	)
Net loss attributable to CYBRDI, INC. AND SUBSIDIARIES	$	(124,868	)	$	(109,836	)	$	(292,747	)	$	(273,526	)

Net Loss Per Common Share
Basic and Diluted	$	(0.00	)	$	(0.00	)	$	(0.00	)	$	(0.00	)

Weighted Average Number of Shares Outstanding
Basic and Diluted		120,225,323			65,756,567			120,225,323			65,756,567

CYBRDI INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)

CYBRDI, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

NOTE A - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

The unaudited consolidated financial statements of Cybrdi Inc. and subsidiaries have been prepared in accordance with U.S. generally accepted accounting principles for interim financial information and pursuant to the requirements for reporting on Form 10-Q. Accordingly, they do not include all the information and footnotes required by accounting principles generally accepted in the United States of America for annual financial statements. However, the information included in these interim financial statements reflects all adjustments (consisting solely of normal recurring adjustments) which are, in the opinion of management, necessary for the fair presentation of the consolidated financial position and the consolidated results of operations. Results shown for interim periods are not necessarily indicative of the results to be obtained for a full year. The consolidated balance sheet information as of December 31, 2011 was derived from the audited consolidated financial statements included in the Company’s Annual Report on Form 10-K. These interim financial statements should be read in conjunction with that report. Certain comparative amounts have been reclassified to conform to the current period's presentation.

The consolidated financial statements include the accounts of Cybrdi, Inc. and its wholly-owned subsidiaries and joint ventures. All material intercompany balances and transactions have been eliminated.

Cybrdi, Inc. (f/k/a Certron Corporation) (the “Company” or “Cybrdi”) was incorporated on August 1, 1966, under the laws of the State of California. Until around June 2004, the Company’s business consisted of the distribution of magnetic media products, primarily blank audio and video cassettes. Due to continuing intense price competition and technological changes in the marketplace for its products, the Company lost its remaining significant customers and disposed of or wrote off its remaining inventory. As a result of these occurrences, the Company concluded that its audio and videotape businesses were no longer viable and some of its product lines were obsolete.

On February 10, 2005, the Company, through a wholly-owned subsidiary, acquired all the ownership interest in Cybrdi, Inc., a privately held company incorporated in the State of Maryland ("Cybrdi Maryland"). As a result of the ownership interests of the former shareholders of Cybrdi Maryland, for financial statement reporting purposes, the transaction was treated as a reverse acquisition, with Cybrdi Maryland deemed the accounting acquirer and Certron Corporation deemed the accounting acquiree. Historical information of the surviving company is that of Cybrdi Maryland.

Cybrdi Maryland was established in 2001 to acquire an interest in biogenetic products commercialization and related services entities in Asia. On March 5, 2003, Cybrdi Maryland acquired an 80% interest in Shaanxi Chao Ying Biotechnology Co., Ltd. (“Chaoying Biotech”), a sino-foreign equity joint venture established in July 2000 in the People's Republic of China (“PRC”), through the exchange of 99% of the Company’s shares to the existing shareholders of Chaoying Biotech. For financial statement reporting purposes, the merger was treated as a reverse acquisition, with Chaoying Biotech deemed the accounting acquirer and Cybrdi Maryland deemed the accounting acquiree.

Chaoying Biotech is a sino-foreign equity joint venture between Shaanxi Chaoying Beauty & Cosmetics Group Co., Ltd. (the “Chinese Partner”, a PRC corporation) and Immuno-Onco Genomics Inc. (the “Foreign Partner”, a USA corporation). The joint venture agreement has a 15 year operating period starting from its formation in July 2000 and it may be extended upon mutual consent. The principal activities of Chaoying Biotech are research, manufacture and sale of various high-quality tissue arrays and the related services in the PRC.

Most of the Company’s activities are conducted through Chaoying Biotech. Chaoying Biotech, with its principal operations located in China, aims to take advantage of China's abundant scientific talent, low wage rates, less stringent biogenetic regulation, and the huge genetic population as it introduces its growing list of tissue micro array products.

On February 10, 2005, the Company completed the merger with Cybrdi Maryland and changed its name to Cybrdi, Inc.

On July 26 , 2007, Chaoying Biotech entered into an acquisition agreement with its Chinese partner, which is a principal shareholder of the company, Mr. Bai, the Company’s chief executive officer and a director is also a principal of its Chinese partner.

On July 28,2007, Chaoying Biotech invested RMB15 millions (equivalent to US$1,983,078) to acquire an 83.33% equity ownership of Shandong Chaoying Culture and Entertainment Co., Ltd. (“SD Chaoying”) from its Chinese partner, SD Chaoying is a corporation organized in Shandong Province P.R.China. On September 5, 2007, Shandong Commercial government had approved this acquisition and the ownership title of SD Chaoying had been transferred to Chaoying Biotech from its Chinese partner. The future business of SD Chaoying will primarily focus on culture and entertainment, including spa activities, cosmetic and personal care, body building, gambling, catering, and lodging, etc. SD Chaoying will have a specific emphasis on casino gambling, which has been approved by Shandong Administration for Civil Affairs. As of December 31, 2009, SD Chaoying had substantially completed the construction of two residential buildings and had recognized revenue from sales of housing for 2009. The main structure of the commercial entertainment center has also been completed, except for the exterior, rooftop, the surrounding supporting projects and the community landscaping, which are expected to be completed in 2012 prior to the commencement of operations by merchant tenants if we can obtain an estimated $2.8 million to complete construction.

On March 10, 2007 the Company entered into a Sales Agency Agreement with BioMax, Ltd., a reseller located in the United States.

On April 29, 2011, Chaoying Biotech invested $154,732 (equivalent to RMB 1 million) to restore the operation of the Institute of Shaanxi Chaoying Clinical Pathology (“IOSCCP”), a wholly-owned subsidiary established on July 31, 2003, whose main business includes pathology research and consulting, consulting and diagnostic clinical pathology and pathology-related research and development of new technologies, and basic training in pathology. Its sole shareholder has been Chaoying Biotech. However, Chaoying Biotech withdrew the original investment from IOSCCP in September 2007 as we believed that both internal and external conditions of IOSCCP were not mature at that time. In light of foreseeable benefits and new business opportunities for this entity, we resumed its business and re-invested $154,732 (equivalent to RMB 1 million) in it in April 2011.

The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred significant losses and has not demonstrated the ability to generate sufficient cash flows from operations to satisfy its liabilities and sustain operations. The Company had an accumulated deficit of $2,740,390 and $2,447,643 as of June 30, 2012 and December 31, 2011, including net losses of $292,747 and $273,526 for the six months ended June 30, 2012 and 2011, respectively. In addition, current liabilities exceeded current assets by $3,211,515 and $2,931,175 at June 30, 2012 and December 31, 2011, respectively. These matters raise substantial doubt about the Company’s ability to continue as a going concern.

The Company finances its operations primarily through short-term bank borrowings and advances from related parties and/or officers/shareholders. In order to complete the construction of SD Chaoying cultural and entertainment center, approximately $3.0 million (equivalent to RMB 19 million) of capital is expected to be needed. The Company, taking into account the available banking facilities, internal financial resource, and supports from related companies, believes it has sufficient working capital to meet its present obligation for at least the next twelve months. Management is taking actions to address the company's financial condition and deteriorating liquidity position. The following sets forth management’s plans for dealing with the adverse effects of the conditions:

(a) Sale of housing inventories: Proceeds to be received from the sale of the remaining housing of the two completed residential buildings are expected to amount to approximately $693,000.

(b) Rental and management fee revenue from the cultural and entertainment center: Annual rental revenue is estimated to be approximately $650,000 per year. Management fee revenue will be charged to commercial tenants at 3% of annual gross revenue. As of June 30, 2012, the Company has not commenced collecting rental and management fee revenue for the culture and entertainment center.

(c) Additional advances from related companies and affiliates: Mr. Bai, our Chief Executive Officer, advanced $55,974 to the Company in the current period to finance operations and the costs to maintain the Company’s public status in the U.S. In addition, Shaanxi Chaoying Beauty & Cosmetics Group, which is also an affiliate, is anticipated to provide up to approximately $791,000 (equivalent to RMB 5 million) of capital to support operations. Shaanxi Chaoying Beauty & Cosmetics Group advanced $12,660 for the current quarter period to the Company to finance its operations.

The Company may require additional funds and may seek to raise such funds though public and private financings or from other sources. There is no assurance that management’s plans will be realized or the additional financing will be available at all or that, if available, such financing will be obtainable on terms favorable to the Company or that any additional financing will not be dilutive. The consolidated financial statements do not include any adjustments that might result from the outcome of those uncertainties.

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ materially from those estimates.

Revenue represents the invoiced value of goods sold recognized upon the delivery of goods to customers and service income is recognized when services are provided. Deferred revenue represents the undelivered portion of invoiced value of goods sold to customers. Sales transactions not meeting all the conditions of the full accrual method are accounted for using the deposit method of accounting. Under the deposit method, all costs are capitalized as incurred, and payments received from the buyer are recorded as customer deposits.

On February 10, 2005, (the "Closing Date") the Company closed on an Agreement and Plan of Merger (the "Agreement") among Certron Corporation (“Certron”), a California corporation, Certron Acquisition Corp., a Maryland corporation and a wholly-owned subsidiary of Certron ("Acquisition Sub"), and Cybrdi, Inc., a Maryland corporation (“Cybrdi – Maryland”) relating to the acquisition by Certron of all of the issued and outstanding capital stock of Cybrdi -Maryland in exchange for shares of common stock of Certron that will aggregate approximately 93.8% of the issued and outstanding common stock of Certron. Pursuant to the terms of the Agreement, at the Closing Date (a) Acquisition Sub has been merged with and into Cybrdi - Maryland, with Cybrdi - Maryland being the surviving corporation, (b) the common stock of Cybrdi-Maryland has been cancelled and converted into the right to receive shares of the common stock of Certron at an exchange ratio of 1.566641609 per share. This resulted in the issuance of 47,328,263 shares of the Certron’s common stock, and (c) each share of the common stock of Acquisition Sub has been converted in to and become one share of the common stock of Cybrdi-Maryland. The share exchange has been accounted for as a reverse merger under the purchase method of accounting. Accordingly, Cybrdi, Inc. will be treated as the continuing entity for accounting purposes and the historical financial statements presented will be those of Cybrdi, Inc.

In connection with the Agreement, on February 10, 2005, the Company amended its articles of incorporation to authorize the issuance of 150 million shares of common stock no par value and 500,000 shares of preferred stock, $1.00 par value per share, none of which are issued or outstanding.

Concurrent with the filing of the Articles of Merger, all of the Company then existing officers and directors tendered their resignation and Yanbiao Bai was appointed as its Chairman of the Board of Directors. Mr. Bai then nominated the balance of the Board of Directors.

Income taxes are provided for the tax effects of transactions reported in the financial statements and consist of taxes currently due plus deferred taxes related primarily to the differences between the basis of assets and liabilities for financial and income tax reporting. The deferred tax assets and liabilities represent the future tax return consequences of those differences, which will either be taxable or deductible when the assets and liabilities are recovered or settled. Deferred taxes also are recognized for operating losses that are available to offset future income taxes.

Currently we are involved in disputes, litigation and other legal proceedings. We prosecute and defend these matters aggressively. However, there are many uncertainties associated with any litigation, and we cannot assure you that these actions or other third party claims against us will be resolved without costly litigation and/or substantial settlement charges. We record a charge equal to at least the minimum estimated liability for a loss contingency when both of the following conditions are met: (i) information available prior to issuance of the financial statements indicates that it is probable that an asset had been impaired or a liability had been incurred at the date of the financial statements and (ii) the range of loss can be reasonably estimated. However, the actual liability in any such disputes or litigation may be materially different from our estimates, which could result in the need to record additional costs.

The Company has adopted all recently issued accounting pronouncements. The adoption of the accounting pronouncements, including those not yet effective, is not anticipated to have a material effect on the financial position or results of operations of the Company.

The June 30, 2012 consolidated balance sheet included total current assets of $1,583,640 and non-current assets of $8,730,312. Of these amounts, $495,492 in cash and equivalents is planned for funding current operations and for future business expansion.

Other current assets also included accounts receivable, inventories, due from related companies, other receivables and prepaid expenses, and advance to suppliers. Inventories are mainly finished goods. Other components of inventories include raw materials, finished goods, and housing inventories. Inventories are stated at the lower of cost or market. Cost of raw materials is determined on the basis of first in first out method (“FIFO”). Finished goods are determined on the weighted average basis and are comprised of direct materials, direct labor, and an appropriate proportion of overhead.

The other primary assets included in current assets are loans to an unaffiliated company, QuanYe Security Co., Ltd (“QuanYe”), an unrelated People’s Republic of China (“PRC”) registered company located in Xian PRC. QuanYe is engaged in the pawnshop business and their primary business is offering alternative financing to small, local companies. According to the loan agreement, QuanYe had received loans from Chaoying Biotech for a total amount of RMB 29.3Million (equivalent to $4,652,640) since January 2006. A remaining balance of RMB 7.3 million (equivalent to $1,159,190) was extended to and expired on March 24, 2008. As of June 30, 2012 and December 31, 2011, the principal balance and interest receivable for this loan had been reduced to $0, net of allowance of $94,444 and $180,258 for doubtful principal balance and interest receivable, respectively. The interest rate for these loans initially was initially 8% per year, and subsequently reduced to 5% since October 9, 2006.

Included in non-current assets are property, plant and equipment, construction-in-progress and intangible assets. Property, plant and equipment mainly consist of building, office equipments, motor vehicles, leasehold improvement, software-website, and machinery used for product manufacturing located in the People’s Republic of China (“PRC”). Depreciation on property, plant and equipment is computed using the straight-line method over the estimated useful life of the assets. The majority of the assets have estimated useful lives of 10 years. Building and office equipment have estimated useful lives of 20 and 5 years, respectively. The “construction in progress” in the amount of $6,781,274 mainly consisted of land under development and construction of the entertainment, culture, and casino facility in Shandong Province, which will be transferred to fixed assets in SD Chaoying when construction is completed. As of June 30, 2012, construction-in-progress of $4.32 million and land use rights of $3.15 million of SD Chaoying were collateralized under a short-term loan from Changle Rural Credit Union. For the $3.15 million land use rights, $2.49 million was classified under construction-in-progress for the commercial property and the remaining $0.66 million was classified under intangible assets subject to amortization. Intangible assets included a tissue chip patent at Chaoying Biotech and $0.66 million of land use rights being put in operation for the partial completed commercial property at SD Chaoying. Effective January 1, 2002, with the adoption of the accounting guidance for Goodwill and Other Intangible Assets, intangible assets with a definite life are amortized on a straight-line basis. The patent is being amortized over its estimated life of 10 years. The land use rights classified in intangible asset is being amortized over its estimated life of 36.9 years through the maturity of the land use rights for commercial use on November 6, 2047.

As of June 30, 2012, the balance sheet included total liabilities of $5,635,305, which consisted of current liabilities of $4,795,155 and construction payable of $840,150. Included in the current liabilities was a short-term loan of $1,495,357 (equivalent to RMB 9.5 million) from Changle Rural Credit Union, which is a bank located in Shandong Province of the PRC. The original term of the loan was from August 25, 2009 to August 24, 2010 with an interest rate of 7.965% per annum. In August 2011, the Company renewed this short-term loan with the same amount of $1,495,357 (equivalent to RMB 9.5 million) with Changle Rural Credit Union. The term of the renewal loan started from August 31, 2011 with a maturity date of August 20, 2012. The adjustable interest rate is a rate per annum equal to the Prime Rate plus 50% of prime rate. The prime rate is based on six-month-to-one-year loan interest rate released by The People's Bank of China. The interest rate for the short-term loan was 9.465% as of June 30, 2012. This short-term loan had been secured by the Company’s land use right and construction-in-progress of SD Chaoying with a book value of $3.15 million (equivalent to RMB 20.03 million) and $4.32 million (equivalent to RMB 27.45 million) as of June 30, 2012, respectively. For the $3.15 million land use rights, $2.49 million was classified under construction-in-progress for the commercial property and the remaining $0.66 million was classified under intangible assets subject to amortization. The Company currently is in process of negotiating with Changle Rural Credit Union to renew the bank loan upon the maturity date on August 20, 2012. Additionally, there is another short-term loan of $157,406 (equivalent to RMB 1.0 million) from Mr. Fengguo Liu, an unrelated party. Also included in the current liabilities was $1,745,801 of loans from related companies, including Xi’an Yanfeng Biotechnology Co., Ltd., Shaanxi Yanfeng Real Estate Co. Ltd, Shaanxi Chaoying Beauty & Cosmetics Group Co., Ltd and the stockholders who are also the Company’s officers. These entities were related to the Company through common ownership and principal officers. These loans are non-interest bearing and have no set repayment terms.

As a result of the reverse merger (see Note A item 6), the common stock of Cybrdi-Maryland has been cancelled and converted into shares of common stock of Certron at an exchange ratio of 1.566641609 per share. This resulted in the issuance of 47,328,263 shares of Certron’s common stock to the Cybrdi shareholders. As of June 30, 2012 and December 31, 2011, the Company had 120,225,323 and 120,225,323 shares issued and outstanding, respectively.

As of June 30, 2012, the balance sheet included total equity of $4,678,647, of which $1,112,330 was for non-controlling interest, representing 20% minority interest in Chaoying Biotech and 16.67% minority interest in SD Chaoying.

On January 15, 2010, the Board of Directors adopted resolutions that authorized incentive compensation to key management of the Company for services it has provided to the Company. As set forth in the Board of Directors’ resolution dated January 15, 2010, the incentive compensation shall be paid by the issuance of 12,000,000 shares of common stock of the Company to Mr. Yanbiao Bai, Chief Executive Officer and President of the Company, and 3,300,000 shares of common stock of the Company to Ms. Xue Bu, the former Chief Financial and Operating Officer of the Company. Compensation cost of $306,000 was recorded during the first quarter of 2010 at $0.02 per share, the market price of the Company’s common stock on January 15, 2010, the grant date.

On June 30, 2011, the Company entered into a written Debt Conversion Agreement with Shaanxi Chaoying Beauty & Cosmetics Group Co., Ltd. (a related party), Shaanxi NuoQi Healthfood Co., Ltd. (a related party), and Mr. Yanbiao Bai, Chairman and CEO of the Company. In the Agreement, the Company agreed to repay a total of $605,723 (RMB 3,920,000) debt due to Shaanxi Chaoying Beauty & Cosmetics Group Co., Ltd. by issuing the Company’s common stock. Simultaneously upon the execution of the repayment, Shaanxi Chaoying Beauty & Cosmetics Group Co., Ltd. agreed to transfer to Mr. Yanbiao Bai the number of shares to be issued through the debt repayment. The number of shares transferred to Mr. Yanbiao Bai was further offset by a number of shares equivalent to $169,973 (RMB 1,100,000) due by Shaanxi NuoQi Health Food Co., Ltd., a company wholly-controlled by Ms. Xue Bu, the spouse of Mr. Yanbiao Bai and former COO and Director of the Company, to offset its debt due to the Company. The Agreement was approved by the Company’s Board of Directors on June 30, 2011. As a result of the debt conversion and offset, the number of shares of common stock issued to Mr. Yanbiao Bai was 54,468,756 shares, which was determined based on the closing price of $0.008 per share on June 30, 2011. The share issuance for repayment of debt as agreed upon and approved was executed on August 17, 2011.

Under the Enterprise Income Tax (“EIT”) of the PRC, prior to 2007, Chinese enterprises are generally subject to an income tax at an effective rate of 33% (30% statutory income taxes plus 3% local income taxes) on income reported in the statutory financial statements after appropriate tax adjustments, unless the enterprise is located in a specially designated region for which more favorable effective tax rates are applicable. Beginning on January 1, 2008, the new EIT law has replaced the existing laws for Domestic Enterprises (“DEs”) and Foreign Invested Enterprises (“FIEs”). The new standard EIT rate of 25% will replace the 33% rate previously applicable to both DES and FIEs. The two year tax exemption, six year 50% tax reduction and tax holiday for production-oriented FIEs will be eliminated. According to the Western Developing Plan implemented by the PRC Government, Chaoying Biotech is entitled to a 50% reduction in EIT of preferential policy, but not less than 15%. As a result, Chaoying Biotech’s effective EIT tax rate has been 15% since 2008.

The Company’s income tax expense includes U.S. and PRC income taxes. There were no U.S. current taxes for the six months ended June 30, 2012 according to net loss incurred in the U.S. entity, which will not be anticipated to have any tax benefit in the future since no revenue is expected to be generated in the U.S as a result of discontinuing the U.S. operating company in Maryland in October 2007. There was $162 of PRC current income taxes accrued for the six months ended June 30, 2012 in SD Chaoying.

On June 7, 2011, Weifang Shili Hesin Engineering Equipment Co., Ltd. (the “Plaintiff”) filed a complaint against SD Chaoying at the Basic People's Court of Changle County in Shandong Province, China, for alleged damages caused by SD Chaoying for not performing appropriately and completely the obligations in accordance with the agreement signed by both parties on April 28, 2011. Pursuant to the agreement, SD Chaoying agreed to transfer: (1) the rights of development, construction, and land of the #1 and #2 residential buildings for RMB 7.6 million, or $1,207,518, and (2) the 12 unsold residential units in the #3 and #4 residential buildings at a price as agreed upon. As of June 30, 2012, the Plaintiff paid $94,444 (equivalent to RMB 600,000) deposit as agreed upon, and prepaid $184,183 (equivalent to RMB 1,170,114), both of which were recorded as Other Payables under current liabilities. Plaintiff was seeking for the discharge of the original agreement signed, the return of prepayment of $184,183 (equivalent to RMB 1,170,114), repayment of the deposit plus 100% penalty, totaling $188,888 (equivalent to RMB 1,200,000), and for attorneys’ fees and costs. The Company disputed Plaintiff’s claim for a land use right certificate of underlying construction base of the #1 and #2 residential buildings, which certificate was inseparable from other part of the land and was not specifically stated in the agreement. The Company also disputed Plaintiff’s entitlement to the amounts claimed and instructed the Company’s legal counsel to contest the action, while concurrently pursuing opportunities for reasonable settlement. The case went to trial on July 7, 2011. On November 15, 2011, the Basic People's Court of Changle County pronounced its judgment against Plaintiff and that SD Chaoying had no liability. However, the plaintiff still has a right to appeal the judgment to the Intermediate Court in Weifang City, Shandong Province, China within 15 days after receiving verdict from the court. The verdict was released by the court on March 23, 2012. An appeal was filed on April 6, 2012 by the Plaintiff after the verdict was released. The court session for the appeal was held on May 16, 2012 at Intermediate Court in Weifang City, Shandong Province, China. As of the date of this report on Form 10-Q, the verdict of the appeal has not yet released by the intermediate court in Weifang City. As of June 30, 2012, the Company has recorded an estimate of loss contingencies of $37,700 under accrued expenses, which was estimated by the Company’s legal counsel to be reasonable. The Company recorded the estimated liability and loss contingencies according to FASB ASC 450-20-25-2 under Topic 450, “Contingencies Loss Contingencies Recognition”.

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operation

The following discussion and analysis should be read in conjunction with the company’s Financial Statements and Notes there to appearing elsewhere in this Report on Form 10-Q as well as the company’s other SEC filings, including our annual report on Form 10-K for the year ended December 31, 2011.

Certain statements in this quarterly report on Form 10-Q contain or may contain forward-looking statements that are subject to known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. These forward-looking statements were based on various factors and were derived utilizing numerous assumptions and other factors that could cause its actual results to differ materially from those in the forward-looking statements. These factors include, but are not limited to, economic, political and market conditions and fluctuations, government and industry regulation, interest rate risk, U.S. and global competition, and other factors. Most of these factors are difficult to predict accurately and are generally beyond its control. You should consider the areas of risk described in connection with any forward-looking statements that may be made herein. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this report. Readers should carefully review this quarterly report in its entirety, including but not limited to its financial statements and the notes thereto. Except for its ongoing obligations to disclose material information under the Federal securities laws, the Company undertakes no obligation to release publicly any revisions to any forward-looking statements, to report events or to report the occurrence of unanticipated events. For any forward-looking statements contained in any document, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. This report on Form 10-Q contains forward-looking statements within the meaning of the federal securities laws. These include statements about our expectations, beliefs, intentions or strategies for the future, which we indicate by words or phrases such as "anticipate," "expect," "intend," "plan," "will," "we believe," "Cybrdi believes," "management believes" and similar language. The forward-looking statements are based on the current expectations of Cybrdi and are subject to certain risks, uncertainties and assumptions, including those set forth in the discussion under "Description of Business" and "Management's Discussion and Analysis." The actual results may differ materially from results anticipated in these forward-looking statements. We base the forward-looking statements on information currently available to us, and we assume no obligation to update them.

The Company focuses on biogenetics commercialization and healthcare product applications. The Company’s primary business includes sales of tissue microarray products and services. Tissue chips, also called micro tissue arrays, provide high-throughput molecular profiling and parallel analysis of biological and molecular characteristics for hundreds of pathologically controlled tissue specimens. Tissue arrays can provide rapid and cost-effective localization and evaluation of proteins, RNA, or DNA molecules, which is particularly useful for functioning genomic studies. Cybrdi manufactures both human and animal tissue microarray for a wide variety of scientific uses, including drug discovery and development purposes.

With its sophisticated research in genes, the Company can provide the professional health diagnostic service for its customers. The Company can check the reasons for obesity and other skin diseases like freckles by its genetic analysis, which offers more accurate and specialized diagnosis than other similar services in the current market. Such information can be utilized to guide customers to set up the right health or fitness program. At present, the Company provide genetic tests for the mechanism of obesity or skin diseases.

The Company will also explore other business development opportunities that can leverage its sales platform and relationship with affiliated companies. Until such time as the Company can identify attractive marketing opportunities, the Company will loan available cash on a short term unsecured basis to non-affiliated third parties in order to generate interest income.

Commencing in the third quarter of 2007, the Company developed a new gene detective tissue array, called New Kits, and began to offer them to its customers.

On July 28, 2007, the Company acquired an 83.33% equity ownership of SD Chaoying from its Chinese partner, which will be primarily engaged in developing and operating culture and entertainment business. The culture and entertainment business will consist primarily of a spa activities, cosmetic personal care, hotel and casino. Its Chinese partner is a principal shareholder of the Company and Mr. Bai, its chief executive officer and a director is also a principal of its Chinese partner. SD Chaoying began constructing the facility in September 2007. The total useable land and net building area for the project consists of approximately 50,000 and 33,000 square meters, respectively of which 52% will constitute property for business use and 48% for residential use. As of June 30, 2012, SD Chaoying had substantially completed the construction of two residential buildings and had recognized revenue from sales of housing units from these buildings. The project includes four multi-family residential buildings (about 14,188 square meters). Approximately 20.88% of the cultural and entertainment part of the facility opened in January 2011 and the balance remains under construction, but is expected to be completed in 2012 prior to the commencement of operations by merchant tenants. SD Chaoying intends to focus on Spa activities, cosmetic personal care, hotel and casino gambling, which has been approved by Shandong Administration for Civil Affairs. In January 2011, SD Chaoying entered into a verbal agreement with Dongshan Victoria Spring Hotel (“Victoria”) allowing Victoria to manage and operate the SPA business at the completed section of the cultural and entertainment facility. SD Chaoying agreed not to charge fees from Victoria during the first year of operation as the trial period. SD Chaoiying and Weifang Shili Hesin Engineering Equipment Co., Ltd. executed an agreement on April 28, 2011, pursuant to which agreement, SD Chaoying agreed to transfer: (1) the rights of development, construction, and land of the #1 and #2 residential buildings for RMB 7.6 million, or approximately $1,206,800, and (2) the 12 unsold residential units in the #3 and #4 residential buildings at a price as agreed upon. As of June 30, 2012, the land use right and construction-in-progress with total book value of $7.47 million (equivalent to RMB 47.5 million) of SD Chaoying were collateralized under the short-term loan of $1,495,357 (equivalent to RMB 9.5 million) from Changle Rural Credit Union.

FOR THE THREE MONTHS ENDED JUNE 30, 2012 COMPARED TO THREE MONTHS ENDED JUNE 30, 2011

Cybrdi mainly generates two categories of revenues, including sales of tissue chip & kits products and residential housing. The net sales decreased $11,012 to $112,407 for the three months ended June 30, 2012 from $123,419 for the three months ended June 30, 2011, a decrease of 8.9% .

Tissue Chip & Kit Products: The net sales decreased $11,012 to $112,407 for the three months ended June 30, 2012 as compared to $123,419 for the three months ended June 30, 2011, a decrease of 8.9% . The decrease in net sales of tissue chip & kit product was primarily due to the decrease in the export sales revenues which accounted for approximately 83.0% of total tissue product sales revenues for the current period. Export sales revenues decreased $21,119 to $93,306 for the three months ended June 30, 2012 , as compared to $114,425 for the three months ended June 30, 2011, a decrease of 18.5% . The sales revenues generated from export sales now are subject to value added tax (VAT) according to PRC tax regulation, whereas the VAT imposed by PRC tax bureau was absorbed by the Company without charging to the customers. Currently, our sole domestic sales representative in China is Xi’an AiLiNa Biotechnology Co., Ltd., and the only overseas sales representative is Biomax. We mainly distribute our products through these two sales representatives.

Housing: SD Chaoying completed the construction of the two six-story multi-family residential buildings with a total of 72 housing units in 2009, 9 and 37 of which units qualified as being recognized as sales revenue aggregating $296,521 and $1,010,632 for the years ended December 31, 2010 and 2009. An additional two residential units were sold in 2011. Another five residential units were qualified as being recognized as sales revenues during the first quarter of 2012. There was no sales from housing in the quarter ended June 30, 2012. Since SD Chaoying is required to continue its involvement with the property after the sale, including installations of utility systems, improvements and amenities, and community landscaping, profit from the sale was recognized using the percentage of completion method as required by ASC Topic 360-20, “Property, Plant, and Equipment – Real Estate Sales”.

Gross margin as a percentage of sales increased to 27.5% for the three months ended June 30, 2012 from 3.3% for the three months ended June 30, 2011.

Tissue Chip & Kit Products: The gross margin of the Tissue Chip & Kit Products division increased to 42.1% for the second quarter of 2012 compared to 17.2% for the same period in 2011. The increase in gross margin for the three months ended June 30, 2012 was mainly because more technical services were rendered to customers in the domestic market and the service incomes were charged to the selling price of products.

Housing: There was no gross profit of the Housing division for the three months ended June 30, 2012 and for the three months ended June 30, 2011, mainly because no housing unit was sold and qualified as being recognized as sales revenues during these quarters.

In addition, the commencement of the business in the commercial property segment has not generated revenue but has incurred costs directly associated with the business.

The Company’s operating expenses increased slightly by $1,788 to $142,803 for the three months ended June 30, 2012 from $141,015 for the three months ended June 30, 2011, an increase of 1.3% . The increase was primarily due to the increase in operating tax expense, salaries and wages, and professional fees, partially offset by the decrease of bad debt expense for the three months ended June 30, 2012. Operating tax expense increased from $54 for the second quarter in 2011 to $10,985 for the second quarter of 2012. Salaries and wages also increased from $41,093 for the second quarter in 2011 to $50,316 for the second quarter of 2012. Also professional fees increased by $8,243 from $10,783 for the second quarter in 2011 to $19,026 for the same period this year. There was no bad debt expense assessed for the three months ended June 30, 2012, whereas the bad debt expense was $23,226 for the same period last year.

Other income decreased by $41,537 to $(42,636) for the three months ended June 30, 2012 as compared to $(1,099) for the three months ended June 30, 2011, a decrease of 3779.5% . The decrease was primarily due to the interest expense of $47,410 for the three months ended June 30, 2012 that was not subject to capitalization due to suspension of the construction of the entertainment center, whereas interest expense was capitalized and recorded as construction-in-progress in the second quarter of 2011.

The Company did not record U.S. current income tax for the three months ended June 30, 2012, and 2011, since there was no taxable income during these periods. There was $162 of PRC current income taxes accrued for the three months ended June 30, 2012 in SD Chaoying.

As a result of the above factors, our net loss before minority interests increased $16,732, or 12.1%, from $137,996 for the three months ended June 30, 2011 to $154,728 for the three months ended June 30, 2012.

FOR THE SIX MONTHS ENDED JUNE 30, 2012 COMPARED TO SIX MONTHS ENDED JUNE 30, 2011

Cybrdi mainly generates two categories of revenues, including sales of tissue chip & kits products and residential housing. The net sales increased $117,287 to $354,517 for the six months ended June 30, 2012 from $237,230 for the six months ended June 30, 2011, an increase of 49.4 %.

Tissue Chip & Kit Products: The net sales decreased $24,913 to $212,317 for the six months ended June 30, 2012 as compared to $237,230 for the six months ended June 30, 2011, a decrease of 10.5% . The decrease in net sales of tissue chip & kit product was primarily due to the decrease in the export sales revenues which accounted for approximately 85.5% of total tissue product sales revenues for the current period. Export sales revenues decreased $34,953 to $181,463 for the six months ended June 30, 2012 , as compared to $216,416 for the six months ended June 30, 2011, a decrease of 16.2% . The sales revenues generated from export sales now are subject to value added tax (VAT) according to PRC tax regulation, whereas the VAT imposed by PRC tax bureau was absorbed by the Company without charging to the customers. Currently, our sole domestic sales representative in China is Xi’an AiLiNa Biotechnology Co., Ltd., and the only overseas sales representative is Biomax. We mainly distribute our products through these two sales representatives.

Gross margin as a percentage of sales increased to 15.2% for the six months ended June 30, 2012 from 6.8% for the six months ended June 30, 2011.

Tissue Chip & Kit Products: The gross margin of the Tissue Chip & Kit Products division increased to 32.0% for the six months ended June 30, 2012 compared to 20.2% for the same period in 2011. The increase in gross margin for the six months ended June 30, 2012 was mainly because more technical services were rendered to customers in the domestic market and the service incomes were charged to the selling price of products.

Housing: The gross margin of the housing division increased to 13.3% for the six months ended June 30, 2012 compared to 0% for the same period in 2011. The increase was mainly due to five housing units being sold and qualified as being recognized as sales revenues during the six-month period in 2012.

In addition, the commencement of the business in the commercial property segment has not generated revenue but has incurred costs directly associated with the business.

The Company’s operating expenses decreased by $42,356 to $300,124 for the six months ended June 30, 2012 from $342,480 for the six months ended June 30, 2011, a decrease of 12.4% . The decrease in operating expenses was primarily because there was no bad debt expense assessed for the six months ended June 30, 2012. Also professional fees decreased from $57,108 for the six months ended June 30, 2011 to $37,735 for the same period in 2012. The decrease of operating expense for the six-month period this year was partially offset by an increase of $27,089 in operating tax expenses from $125 for the six months ended June 30, 2011 to $27,214 for the six months ended June 30, 2012, and an increase of salaries and wages of $20,984 to $102,560 for the six months ended June 30, 2012 from $81,576 for the same period last year.

Other income decreased by $114,314 to $(114,683) for the six months ended June 30, 2012 as compared to $(369) for the six months ended June 30, 2011, a decrease of 30979.4% . The decrease was primarily due to the interest expense of $94,020 for the six months ended June 30, 2012 that was not subject to capitalization due to suspension of the construction of the entertainment center, whereas interest expense was capitalized and recorded as construction-in-progress for the same period in 2011.

The Company did not record U.S. current income tax for the six months ended June 30, 2012, and 2011, since there was no taxable income during these periods. There was $162 of PRC current income taxes accrued for the six months ended June 30, 2012 in SD Chaoying.

As a result of the above factors, our net loss before minority interests increased $34,377, or 10.5%, from $326,695 for the six months ended June 30, 2011 to $361,072 for the six months ended June 30, 2012.

Operating working capital deficit (total current asset deduct total current liabilities) decreased by $280,340 from $(2,931,175) as of December 31, 2011 to $(3,211,515) as of June 30, 2012. The decrease was primarily due to a decrease of $131,432 in inventories from $1,053,038 as of December 31, 2011 to $921,606 as of June 30, 2012 , an increase of $53,321 in accrued expense from $693,436 as of December 31, 2011 to $746,757 as of June 30, 2012, and an increase of $60,850 in other payables from $366,020 as of December 31, 2011 to $426,870 as of June 30, 2012.

For investing activities, the Company incurred net cash outflow during the six months ended June 30, 2012. The primary reason was due to $62,077 used in the construction in progress of the SD Chaoying project during the six months ended June 30, 2012.

For financing activities, the Company obtained net proceeds of $50,635 and $104,273 from related parties and shareholders/officers of the Company, respectively for the six months ended June 30, 2012, partially offset by the repayments of loan from the Company’s shareholders/officers of $253,173 for the six months ended June 30, 2012.

The Company has a short-term loan in the principal amount of $1,495,357 (equivalent to RMB 9.5 million) with Changle Rural Credit Union. The loan has a maturity date of August 20, 2012. The adjustable interest rate is a rate per annum equal to the prime rate plus 50% of the prime rate. The prime rate is based on six-month-to-one-year loan interest rate released by the People's Bank of China. The interest rate for the short-term loan was 9.465% as of June 30, 2012. This short-term loan had been secured by the Company’s land use right and construction-in-progress of SD Chaoying with a book value of $3.15 million (equivalent to RMB 20.03 million) and $4.32 million (equivalent to RMB 27.45 million) as of June 30, 2012, respectively. The Company currently is in process of negotiating with Changle Rural Credit Union to renew the bank loan upon the maturity date on August 20, 2012.

The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred significant losses and has not demonstrated the ability to generate sufficient cash flows from operations to satisfy its liabilities and sustain operations. The Company had an accumulated deficit of $2,740,390 and $2,447,643 as of June 30, 2012 and December 31, 2011, including net losses of $292,747 and $273,526 for the six months ended June 30, 2012 and 2011, respectively. In addition, current liabilities exceeded current assets by $3,211 515 and $2,931,175 as of June 30, 2012 and December 31, 2011, respectively. These matters raise substantial doubt about the Company’s ability to continue as a going concern.

The Company finances its operations primarily through short-term bank borrowings and advances from related parties and/or officers/shareholders. In order to complete the construction of SD Chaoying cultural and entertainment center, approximately $3.0 million (equivalent to RMB 19 million) of capital is expected to be needed. The Company, taking into accounts the available banking facilities, internal financial resource, and supports from related companies, believes it has sufficient working capital to meet its present obligation for at least the next twelve months. Management is taking actions to address the company's financial condition and deteriorating liquidity position. The following sets forth management’s plans for dealing with the adverse effects of the conditions:

(a) Sale of housing inventories: Proceeds to be received from the sale of the remaining housing of the two completed residential buildings are expected to amount to approximately $693,000.

Shaanxi Chaoying Beauty & Cosmetics Group advanced $12,660 for the three months ended June 30, 2012 to the Company to finance its operations.

A smaller reporting company is not required to provide the information required by this Item .

Evaluation of Disclosure Controls and Procedures. The term “disclosure controls and procedures” (defined in SEC Rule 13a-15(e)) refers to the controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files under the Securities Exchange Act of 1934 (the “Exchange Act”) is recorded, processed, summarized and reported within required time periods. Under the supervision and with the participation of our management, including our Chief Executive Officer, Yanbiao Bai, and Principal Financial Officer, Yonghong Ren, we evaluated the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this report. Based upon that evaluation, our Chief Executive Officer and Principal Financial Officer concluded that our disclosure controls and procedures as of the end of the period covered by this report were effective such that the information required to be disclosed by us in reports filed under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms and (ii) accumulated and communicated to our management to allow timely decisions regarding disclosure. A controls system cannot provide absolute assurance, however, that the objectives of the controls system are met, and no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within a company have been detected.

Changes in Internal Control Over Financial Reporting. The term “internal control over financial reporting” (defined in SEC Rule 13a-15(f)) refers to the process of a company that is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. During the most recent quarter ended June 30, 2012, there has been no change in our internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

On June 6, 2000, we received a notice to inform us that we may have a potential liability from waste disposal in the Casmalia Disposal Site at Santa Barbara County, California. We were given a choice of either signing an agreement that would toll the statute of limitations for eighteen (18) months in order to allow us to resolve any liability with the government without incurring costs associated with being named a defendant in a lawsuit, or becoming an immediate defendant in a lawsuit. We signed the tolling agreement. On November 20, 2001, the tolling agreement was extended for an additional 18 months. On May 20, 2003 the tolling agreement was again extended for an additional 18 months and on November 24, 2004 the tolling agreement was again extended for additional 18 months. On June 29, 2004, we received a proposed settlement from the EPA in the amount of $21,131, which had been accrued as other payable. We are waiting for communication from the government concerning payment of the final settlement. As of June 30, 2012, the Company had not received further correspondences from the EPA regarding this matter.

On June 7, 2011, Weifang Shili Hesin Engineering Equipment Co., Ltd. (the “Plaintiff”) filed a complaint against SD Chaoying at the Basic People's Court of Changle County in Shandong Province, China, for alleged damages caused by SD Chaoying for not performing appropriately and completely the obligations in accordance with the agreement signed by both parties on April 28, 2011. Pursuant to the agreement, SD Chaoying agreed to transfer: (1) the rights of development, construction, and land of the #1 and #2 residential buildings for RMB 7.6 million, or $1,207,518, and (2) the 12 unsold residential units in the #3 and #4 residential buildings at a price as agreed upon. As of June 30, 2012, the Plaintiff paid $94,444 (equivalent to RMB 600,000) deposit as agreed upon, and prepaid $184,183 (equivalent to RMB 1,170,114), both of which were recorded as Other Payables under current liabilities. Plaintiff was seeking for the discharge of the original agreement signed, the return of prepayment of $184,183 (equivalent to RMB 1,170,114), repayment of the deposit plus 100% penalty, totaling $188,888 (equivalent to RMB 1,200,000), and for attorneys’ fees and costs. The Company disputed Plaintiff’s claim for a land use right certificate of underlying construction base of the #1 and #2 residential buildings, which certificate was inseparable from other part of the land and was not specifically stated in the agreement. The Company also disputed Plaintiff’s entitlement to the amounts claimed and instructed the Company’s legal counsel to contest the action, while concurrently pursuing opportunities for reasonable settlement. The case went to trial on July 7, 2011. On November 15, 2011, the Basic People's Court of Changle County pronounced its judgment against Plaintiff and that SD Chaoying had no liability. However, the plaintiff still has a right to appeal the judgment to the Intermediate Court in Weifang City, Shandong Province, China within 15 days after receiving verdict from the court. The verdict was released by the court on March 23, 2012. An appeal was filed on April 6, 2012 by the Plaintiff after the verdict was released. The court session for the appeal was held on May 16, 2012 at Intermediate Court in Weifang City, Shandong Province, China. As of the date of this report on Form 10-Q, the verdict of the appeal has not yet been released by the intermediate court in Weifang City. As of June 30, 2012, the Company has recorded an estimate of loss contingencies of $37,700 under accrued expenses, which was estimated by the Company’s legal counsel to be reasonable. The Company recorded the estimated liability and loss contingencies according to FASB ASC 450-20-25-2 under Topic 450, “Contingencies Loss Contingencies Recognition”.

Other than stated above, there are no material pending legal proceedings to which the Registrant is a party or as to which any of its property is subject, and no such proceedings are known to the Registrant to be threatened or contemplated against it.

A smaller reporting company is not required to provide the information required by this Item.

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized.

Large accelerated filer	Accelerated filer	Non-accelerated filer	Smaller reporting company
[ ]	[ ]	[ ]	[X]
		(Do not check if a smaller
		reporting company)


FORM 10-Q
QUARTERLY PERIOD ENDED JUNE 30, 2012
INDEX

TABLE OF CONTENTS

		Page
PART I – FINANCIAL INFORMATION
Item 1:	Financial Statements	4
Item 2:	Management’s Discussion and Analysis of Financial Condition and Results of Operations	5
Item 3:	Quantitative and Qualitative Disclosures About Market Risk	13
Item 4T:	Controls and Procedures	13
PART II – OTHER INFORMATION
Item 1:	Legal Proceedings	14
Item 1A:	Risk Factors	14
Item 2:	Unregistered Sales of Equity Securities and Use of Proceeds	15
Item 3:	Defaults Upon Senior Securities	15
Item 4:	Mine Safety Disclosures	15
Item 5:	Other Information	15
Item 6:	Exhibits	15

		June 30, 2012			December 31, 2011
ASSETS		(Unaudited)			(Audited)

CURRENT ASSETS
Cash and equivalents	$	495,492		$	781,048
Accounts receivable, net		3,125			-
Inventories		921,606			1,053,038
Due from related companies		90,331			79,442
Other receivables, net and prepaid expenses		72,456			75,089
Advance to suppliers		630			832
TOTAL CURRENT ASSETS		1,583,640			1,989,449
PROPERTY, PLANT AND EQUIPMENT, NET		1,233,391			1,310,529
CONSTRUCTION IN PROGRESS		6,781,274			6,829,329
INTANGIBLE ASSETS, NET		715,647			782,215

TOTAL ASSETS	$	10,313,952		$	10,911,522

LIABILITIES AND EQUITY

CURRENT LIABILITIES
Short-term loan	$	1,652,762		$	1,668,282
Accounts payable		3,318			4,942
Accrued expenses		746,757			693,436
Deferred revenue		123,370			139,284
Customers deposits		86,080			188,186
Due to related parties		1,745,801			1,850,181
Deferred tax liabilities		10,197			10,293
Other payables		426,870			366,020
TOTAL CURRENT LIABILITIES		4,795,155			4,920,624
CONSTRUCTION PAYABLE		840,150			894,750
TOTAL LIABILITIES		5,635,305			5,815,374

EQUITY
Preferred Stock, $1.00 per value, 500,000 shares authorized, no shares issued and outstanding		-			-
Common Stock, no par value, 150,000,000 shares authorized, and 120,225,323 and 120,225,323 shares issued and outstanding, respectively		4,313,614			4,313,614
Additional paid-in capital		172,308			172,308
Reserve funds		336,885			336,885
Accumulated deficit		(2,740,390	)		(2,447,643	)
Accumulated other comprehensive income		1,483,900			1,540,329
TOTAL STOCKHOLDERS’ EQUITY		3,566,317			3,915,493
NONCONTROLLING INTEREST		1,112,330			1,180,655
TOTAL EQUITY		4,678,647			5,096,148

TOTAL LIABILITIES AND EQUITY	$	10,313,952		$	10,911,522

		Six Months Ended			Six Months Ended
		June 30, 2012			June 30, 2011

CASH FLOWS FROM OPERATING ACTIVITIES
Net Loss	$	(292,747	)	$	(273,526	)
Adjustments to Reconcile Net Loss to Net Cash
Provided by Operating Activities:
Depreciation and amortization		125,081			135,345
Bad debt expense		-			68,830
Minority interest		(68,325	)		(53,169	)
Changes in Operating Assets and Liabilities:
Accounts receivable		(3,142	)		-
Inventories		122,276			(15,636	)
Other receivable and prepaid expenses		1,189			(3,365	)
Accounts payable and other current liabilities		93,345			81,043
Deferred revenue		10,378			-
Customer deposits		(100,883	)		906
Net Cash Used in Operating Activities		(112,828	)		(59,572	)

CASH FLOWS FROM INVESTING ACTIVITIES
Advance for loan to affiliated companies		(5,845	)		(38,480	)
Purchase of property, plant, and equipment		(190	)		(46,523	)
Payments for construction in progress		(62,077	)		(87,100	)
Net Cash Used in Investing Activities		(68,112	)		(172,103	)

CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from loans from related companies		50,635			36,710
Proceeds from shareholders/officers		104,273			122,469
Repayments of loan from shareholders/officers		(253,173	)		-
Net Cash (Used in) Provided by Financing Activities		(98,265	)		159,179

NET DECREASE IN CASH & CASH EQUIVALENTS		(279,205	)		(72,496	)
EFFECT OF EXCHANGE RATE CHANGE ON CASH & CASH EQUIVALENTS		(6,351	)		11,684
CASH & CASH EQUIVALENTS, BEGINNING BALANCE		781,048			585,020

CASH & CASH EQUIVALENTS, ENDING BALANCE	$	495,492			524,208

SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION
Interest paid	$	75,031			86,084
Income taxes paid	$	-			-

Exhibit Number	Description
31.1	Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2	Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1	Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2	Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

CONSOLIDATED STATEMENTS OF OPERATIONS


		Three Months Ended			Three Months Ended
		June 30, 2012			June 30, 2011		$ Change		% Change
Revenue
Housing	$	-		$	-		-		0.0%
Commercial rental		-			-		-		0.0%
Tissue array products		112,407			123,419		(11,012	)	-8.9%
Total revenue		112,407			123,419		(11,012	)	-8.9%
Cost of Sales
Housing		-			-				0.0%
Commercial rental		16,414			17,125		(711	)	-4.2%
Tissue array products		65,120			102,176		(37,056	)	-36.3%
Total cost of sales		81,534			119,301		(37,767	)	-31.7%

Gross Profit		30,873			4,118		26,755		649.7%

Operating Expenses:
Salaries and wages		50,316			41,093		9,223		22.4%
Depreciation and amortization		36,561			36,721		(160	)	-0.4%
Professional fees		19,026			10,783		8,243		76.4%
Operating tax expenses		10,985			54		10,931		20242.6%
Selling and distribution expenses		1,374			3,786		(2,412	)	-63.7%
Other general and administrative expenses		24,541			25,352		(811	)	-3.2%
Bad debt expense		-			23,226		(23,226	)	-100.0%
Total Operating Expenses		142,803			141,015		1,788		1.3%

Loss from Operations		(111,930	)		(136,897	)	24,967		-18.2%

Other Income
Net interest expense		(46,132	)		(1,085	)	(45,047	)	4151.8%
Other (expense) income, net		3,496			(14	)	3,510		-25071.4%
Total Other Expense, Net		(42,636	)		(1,099	)	(41,537	)	3779.5%

Loss before Income Taxes		(154,566	)		(137,996	)	(16,570	)	12.0%
Income Tax Expense		(162	)		-		(162	)	100.0%
Net loss		(154,728	)		(137,996	)	(16,732	)	12.1%
Net loss attributable to the noncontrolling interest		(29,860	)		(28,160	)	(1,700	)	6.0%
Net loss attributable to CYBRDI, INC. AND SUBSIDIARIES	$	(124,868	)	$	(109,836	)	(15,032	)	13.7%

101.	INS† XBRL Instance Document.
101.	SCH† XBRL Taxonomy Extension Schema Document.
101.	CAL† XBRL Taxonomy Extension Calculation Linkbase Document.
101.	DEF† XBRL Taxonomy Extension Definition Linkbase Document.
101.	LAB† XBRL Taxonomy Extension Label Linkbase Document.
101.	PRE† XBRL Taxonomy Extension Presentation Linkbase Document.

	CYBRDI, INC.

DATE: August 14, 2012	By /s/ Yanbiao Bai
	Yanbiao Bai, Chief Executive Officer and president

	By /s/ Yonghong Ren
	Yonghong Ren, Principal Financial Officer